In breast cancer, for example, despite the approval of over 20 new agents targeting HER2 since 2000, the Surveillance, Epidemiology, and End Results program of the United States National Cancer Institute data indicate that OS has not substantially improved during this period. Here, ERBB2 is linked to breast carcinoma.